Zolpidem

Introduction Overview

Generic Name

zolpidem

Brand Name

Ambien, Ambien CR, Edluar, Zolpimist, Intermezzo

Dosage Form

oral capsule, oral tablet (immediate and extended release), sublingual tablet, oral spray

Drug Class

Miscellaneous anxiolytics, sedatives and hypnotics

Pharmacokinetics

Absorption:
Zolpidem is rapidly absorbed from the gastrointestinal tract after oral administration, with peak plasma concentrations typically reached within approximately 1.5 hours for immediate-release formulations. The drug’s absorption can be delayed if taken with food, particularly a high-fat meal, which may result in a slower onset of action and reduced peak levels, thus delaying sleep induction. Sublingual and orally disintegrating tablet formulations are designed to provide rapid absorption through the oral mucosa, enhancing onset for middle-of-the-night dosing.

Distribution:
Following absorption, zolpidem exhibits an apparent volume of distribution of approximately 0.54 L/kg, indicating moderate distribution into body tissues. It is approximately 92.5% bound to plasma proteins, mainly albumin, which influences its free active drug concentration and pharmacologic effect. Due to its lipophilicity, zolpidem readily crosses the blood-brain barrier to exert central nervous system effects. It also crosses the placenta and is excreted into breast milk.

Metabolism:
Zolpidem undergoes extensive hepatic metabolism primarily via oxidation by cytochrome P450 enzymes, predominantly CYP3A4, and to a lesser extent CYP1A2 and CYP2C9. The major metabolic pathways include hydroxylation and subsequent glucuronidation, producing pharmacologically inactive metabolites. Factors affecting hepatic metabolic capacity, such as liver disease or co-administration of CYP3A4 inhibitors, can significantly alter zolpidem plasma concentrations and clinical effects.

Elimination:
The elimination half-life of zolpidem ranges between 2.5 to 3 hours in healthy adults, reflecting rapid clearance, which supports its indication for sleep induction rather than prolonged sedation. Excretion is primarily renal, with approximately 70% of the dose recovered in urine as metabolites, and minor amounts eliminated in feces. Impaired renal or hepatic function can prolong zolpidem’s elimination, necessitating dosage adjustments particularly in elderly or medically compromised populations.

Dosage Forms

Available Dosage Forms:
- Oral capsule: 7.5 mg
- Oral tablet (immediate release): 5 mg, 10 mg
- Oral tablet (extended release, Ambien CR): 6.25 mg, 12.5 mg
- Sublingual tablet (Edluar, Intermezzo): 1.75 mg, 3.5 mg, 5 mg, 10 mg
- Oral spray (Zolpimist): formulations consistent with immediate-release dosing

Dosages for Adults and Adolescents:
- Immediate-release (IR) tablets, oral spray, and sublingual tablets (5 and 10 mg):
Women typically start at 5 mg orally once daily at bedtime;
Men may receive 5 to 10 mg once daily at bedtime;
Maximum dose: 10 mg/day.
- Extended-release (CR/ER) tablets:
Women: 6.25 mg once daily at bedtime;
Men: 6.25 to 12.5 mg once daily at bedtime;
Maximum dose: 12.5 mg/day.
- Sublingual tablets (1.75 and 3.5 mg):
Used as needed upon middle-of-the-night awakening with trouble falling back asleep;
Women: 1.75 mg once daily max;
Men: 3.5 mg once daily max.

Specific Patient Populations:
- Geriatric patients: Lower initial doses are recommended due to increased sensitivity and slower clearance.
- IR tablets, oral spray, and sublingual tablets: 5 mg once daily (max 5 mg/day).
- CR tablets: 6.25 mg once daily (max 6.25 mg/day).
- Sublingual tablets: 1.75 mg once as needed (max 1.75 mg/day).
- Patients with hepatic or renal impairment require cautious dosing due to prolonged elimination half-life.
- Dosing regimens differ between men and women, reflecting sex-based pharmacokinetic differences; women require approximately half the dose of men.
- The sublingual tablet formulations (Edluar and Intermezzo) are not indicated if less than 4 hours of bedtime remain before planned awakening.

Mechanism Of Action

Zolpidem exerts its sedative-hypnotic effects primarily through selective modulation of the gamma-aminobutyric acid (GABA) neurotransmitter system, the principal inhibitory pathway in the central nervous system. It specifically binds to the benzodiazepine-1 (BZ1) receptor subtype located on the alpha-1 subunit of the GABA_A receptor complex. By enhancing GABA-mediated chloride ion influx, zolpidem hyperpolarizes neuronal membranes, leading to central nervous system depression that facilitates the onset of sleep.

Unlike classical benzodiazepines, zolpidem has a high affinity for the BZ1 subtype, which is thought to account for its hypnotic properties with minimal anxiolytic, muscle relaxant, or anticonvulsant effects. This receptor selectivity results in a more targeted sedative effect to promote sleep initiation while reducing some adverse effects commonly associated with benzodiazepines. Zolpidem-induced GABA_A receptor modulation increases inhibitory neurotransmission, which dampens neuronal excitability in arousal-promoting brain regions such as the reticular activating system.

Clinically, zolpidem’s unique receptor binding profile explains its rapid onset and relatively short duration of action, making it suitable for treatment of sleep-onset insomnia. This targeted mechanism also contributes to its favorable safety profile compared to benzodiazepines, although dependence and tolerance can still occur with prolonged use. Research studies have demonstrated that zolpidem alters electroencephalographic sleep architecture by increasing non-rapid eye movement (NREM) sleep, specifically stages N2 and N3, enhancing sleep efficiency without significant suppression of REM sleep.

Comparatively, other hypnotic agents such as benzodiazepines bind non-selectively to multiple GABA_A receptor subtypes, while newer agents like eszopiclone and zaleplon exhibit varying receptor subtype selectivity. Understanding zolpidem’s mechanism has informed the development of additional agents that seek to maximize efficacy in sleep induction while minimizing residual sedation and dependence risk.

Pharmacological Actions

Selective agonist at benzodiazepine-1 (BZ1) receptor sites on the GABA_A receptor complex.
Potentiation of GABAergic inhibitory neurotransmission resulting in CNS depression.
Induces sedation and hypnosis primarily by facilitating chloride ion influx and neuronal hyperpolarization.
Promotes sleep onset and improves sleep initiation latency.
Minimal anxiolytic, muscle relaxant, or anticonvulsant activity compared to classical benzodiazepines.
Rapid onset of action due to high lipophilicity and brain penetration.
Short elimination half-life minimizing next-day residual sedation at recommended doses.
Modifies sleep architecture by increasing non-REM sleep while minimally affecting REM sleep.
Potential for physical and psychological dependence with prolonged or high-dose use.
Produces amnesic effects, which may manifest as anterograde amnesia and complex sleep behaviors.
Exhibits sex-dependent pharmacokinetics impacting dosing recommendations.
Reduced effect on respiratory drive compared to barbiturates, but caution needed with respiratory disease.
Produces dose-dependent CNS depression with potential additive effects when combined with other CNS depressants.
Has limited muscle relaxant properties, reducing fall risk related to motor impairment compared to benzodiazepines.
Can produce paradoxical reactions including agitation, aggression, or hallucinations in susceptible individuals.

Therapeutic Or Clinical Uses

Short-term treatment of insomnia characterized by difficulties with sleep initiation.
Management of insomnia with difficulties in sleep maintenance using extended-release formulations.
Treatment of middle-of-the-night awakenings accompanied by difficulty returning to sleep (using sublingual tablets).
Adjunctive use in patients requiring rapid sleep onset without extended sedation.
Alternative to benzodiazepines for hypnotic therapy in adults with sleep disorders.
Improvement of sleep quality by increasing total sleep time and reducing nighttime awakenings.
Employed in patients who are at risk of benzodiazepine dependence due to different receptor selectivity.
Utilized in geriatric populations with dose adjustment to minimize adverse effects and excessive sedation.
Used in clinical practice to decrease sleep latency with minimal next-day psychomotor impairment.
Treatment option alongside cognitive-behavioral therapy for insomnia for optimal management.
Employed in cases where non-pharmacologic interventions have failed or are impractical.
Used cautiously in patients with mild to moderate hepatic impairment with dose adjustments.
Suitable for patients with co-morbid anxiety without significant anxiolytic effects.
Considered for patients with transient or situational insomnia due to its short half-life.
Avoided for long-term use generally exceeding 4 weeks due to potential for tolerance and dependence.

Side Or Adverse Effects

Daytime drowsiness and residual sedation.
Dizziness and feeling light-headed or 'drugged'.
Headache, often mild to moderate in intensity.
Gastrointestinal disturbances such as diarrhea.
Anterograde amnesia leading to memory problems related to the dosing period.
Complex sleep-related behaviors: sleep-driving, sleep-eating, sleep-calling, with no memory of events.
Confusion, particularly in elderly or cognitively impaired patients.
Hallucinations and unusual thoughts or behavioral changes.
Allergic reactions ranging from rash, hives, to angioedema.
Paradoxical reactions including agitation, aggression, and anxiety.
Respiratory depression risk in patients with compromised lung function.
Dependence and withdrawal symptoms upon abrupt discontinuation.
Risk of falls, especially in elderly due to impaired balance or coordination.
Potential for abuse and addiction with prolonged or inappropriate use.
Rebound insomnia following cessation of treatment.

Precautions

Avoid use in patients with known hypersensitivity to zolpidem or its components.
Use with caution in patients with respiratory disorders such as sleep apnea or COPD.
Monitor patients with a history of depression, agitation, or suicidal ideation closely.
Avoid concomitant use with alcohol or other CNS depressants due to additive sedation.
Not recommended for use in children or adolescents under 18 years of age.
Adjust dosing or avoid use in hepatic impairment due to decreased clearance.
Use caution in elderly patients due to increased sensitivity and risk of adverse effects.
Do not exceed prescribed dose or duration; risk of dependence and overdose exists.
Advise patients to ensure they have a full 7-8 hours available for sleep after dosing.
Pregnancy category C: Use only if potential benefits justify risk to fetus; avoid in last trimester.
Patients should avoid driving or hazardous activities until response to drug is known.
Avoid use if patient has a history of engaging in activities like sleep-walking or complex behavior under sedatives.
Regular assessment for signs of misuse, abuse, or addiction is recommended.
Use caution during breastfeeding; avoid nursing within 23 hours of dosing to prevent infant exposure.
Consider dose adjustments in renal impairment although limited data available.

Warnings

Do not use in larger amounts or for longer than prescribed to avoid serious adverse effects.
May cause complex sleep behaviors (sleep-walking, sleep-driving) with no memory afterwards; discontinue if observed.
Risk of severe allergic reactions, including anaphylaxis and angioedema.
Patients may experience impaired alertness and psychomotor function the morning after use, especially with extended-release forms and in women.
Avoid alcohol consumption during treatment as it increases risk of respiratory depression and sedation.
Do not use zolpidem if prior episodes of sleep-related complex behaviors with other sedative-hypnotics have occurred.
Not recommended for use in patients with a history of drug or alcohol abuse due to potential for addiction.
Risk of respiratory depression, especially in patients with underlying pulmonary disease.
Avoid operating machinery or driving until fully alert the morning after administration.
Abrupt discontinuation may cause withdrawal symptoms including anxiety and agitation.
Careful consideration advised in patients with depression or suicidal tendencies.
Use in pregnancy only if clearly needed; potential teratogenic or neonatal adverse effects in late pregnancy.
Overdose can be fatal, signs include severe drowsiness, confusion, shallow breathing, or coma.
Keep medication out of reach of children; accidental ingestion can be dangerous.
Drug misuse, recreational use, and diversion are significant concerns; store securely.

Contraindication

Hypersensitivity to zolpidem or any of its excipients.
Patients who have previously exhibited complex behaviors such as sleep-driving or sleep-related activities while using zolpidem or similar hypnotics.
Severe hepatic impairment due to reduced drug clearance and increased sedation risk.
Known history of substance abuse or dependence to sedative hypnotics without adequate supervision.
Use in children and adolescents under 18 years of age, safety and efficacy not established.
Concomitant use with other central nervous system depressants where additive effects cannot be safely managed.
Acute respiratory failure or respiratory insufficiency where CNS depressants could exacerbate breathing problems.
Myasthenia gravis due to risk of worsening muscle weakness and respiratory compromise.
Severe respiratory disorders including untreated sleep apnea syndrome.
Patients experiencing suicidal ideation where hypnotic use may increase risk.

Drug Interactions

Additive CNS depressant effects with alcohol, benzodiazepines, opioids, muscle relaxants, and other sedatives.
Increased zolpidem plasma concentration and effect with potent CYP3A4 inhibitors such as ketoconazole and erythromycin.
Decreased zolpidem efficacy due to CYP3A4 inducers like rifampin, carbamazepine, and phenytoin.
Enhanced sedation and respiratory depression risk with concomitant use of opioid analgesics.
Potential additive impairment of cognitive and motor functions when combined with antidepressants like fluoxetine and sertraline.
Risk of enhanced sedation and respiratory depression when co-administered with antiepileptic drugs.
Interaction with St. John's Wort may reduce zolpidem plasma concentrations due to induction of hepatic enzymes.
Concurrent use with other hypnotics or anxiolytics intensifies sedative effects and risk of overdose.
Antihistamines or other anticholinergic agents can potentiate zolpidem's sedative effects.
Concomitant use with drugs that prolong QT interval should be monitored closely.
May interact with warfarin affecting coagulation parameters indirectly due to altered metabolism.
Caution with concomitant use of herbal supplements that affect CNS or hepatic metabolism.
Interactions may lead to increased risk of daytime sedation, cognitive impairment, and falls.
Co-administration with HIV protease inhibitors may require dose adjustment and monitoring.
Multiple drug interactions necessitate careful medication reconciliation when prescribing zolpidem.

Preparations Of The Drug

Immediate-release oral tablets: 5 mg and 10 mg (Ambien, Edluar, Zolpimist).
Extended-release oral tablets: 6.25 mg and 12.5 mg (Ambien CR).
Sublingual tablets: 1.75 mg, 3.5 mg, 5 mg, and 10 mg (Edluar, Intermezzo).
Oral spray formulation for rapid absorption (Zolpimist).
Formulations designed for different clinical indications including sleep onset and middle-of-the-night awakenings.
Packages include safety information emphasizing dose timing and sleep duration requirements.
Original container packaging to protect from moisture, heat, and light.
Patient labeling includes information on proper administration, storage, and disposal.
Available as generic and branded versions to facilitate patient accessibility.
Non-chewable, non-crushable dosage forms to reduce misuse and maintain extended-release properties.
Prescribed as part of short-term insomnia treatment regimens with emphasis on limited duration.
Co-packaging with medication guides and pharmacy counseling is standard.
Orally disintegrating tablets designed for ease of administration without water.
Formulation excipients carefully selected to minimize allergenic potential and improve stability.
Available through prescription only, with controlled dispensing to prevent abuse.